Daily Vitamin D increased HDAC2 and 25(OH)D levels in stable COPD patients without improving pulmonary function.

This experimental study investigated the effects of Vitamin D supplementation in a small cohort of five stable COPD patients treated at Jemursari Islamic Hospital. Participants received a daily dose of 5000 IU of Vitamin D for a follow-up period of three months. No comparator group was reported in this study.

Regarding primary and secondary outcomes, the intervention was associated with a significant increase in serum 25(OH)D levels. Concurrently, HDAC2 expression levels also demonstrated a significant increase. However, analysis of pulmonary function parameters revealed only an increasing trend, with no statistically significant differences observed between baseline and follow-up measurements.

Safety and tolerability data were not reported, as no adverse events, serious adverse events, discontinuations, or specific tolerability metrics were documented in the available information. The study authors note that while Vitamin D supplementation was associated with increased HDAC2 levels, the lack of significant improvement in pulmonary function limits immediate clinical application.

Key limitations include the very small sample size of five patients and the absence of a control group. The practice relevance suggests a potential anti-inflammatory effect based on molecular markers, but the clinical impact needs further studies to determine if these molecular changes translate to meaningful patient outcomes.